Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1989-04

AUTHORS

S. G. Spiro, R. L. Souhami, D. M. Geddes, C. M. Ash, H. Quinn, P. G. Harper, J. S. Tobias, M. Partridge, D. Eraut

ABSTRACT

A total of 610 patients with small cell lung cancer were entered into a randomised trial designed to assess the effect of duration of initial chemotherapy on survival. Patients were randomised to receive either four or eight courses of cytotoxic chemotherapy with cyclophosphamide, vincristine and etoposide and also randomised to receive, on disease progression, either second line chemotherapy (methotrexate and doxorubicin) or symptomatic treatment only. In the whole study 196 (32.1%) had limited disease and 414 (67.9%) extensive disease. During initial chemotherapy the response rate (complete and partial responses) after four courses of treatment was 61% with no significant increase in patients receiving eight courses (63%). In those randomised to receive relapse chemotherapy the response rate was improved slightly for those who had originally received four courses of chemotherapy (25.6%) over those receiving eight (18.7%). The overall results show that of the four possible treatment randomizations, four courses of chemotherapy alone is inferior in terms of overall survival (30 weeks median survival) to the other three treatment options (39 weeks median survival, P less than 0.01). In patients responding to initial chemotherapy the disadvantage of four courses of chemotherapy alone was apparent (median survival of 40 weeks versus 49 weeks, P = 0.003) but not if drug treatment was given on relapse. The study shows that limiting treatment to four courses of chemotherapy alone is associated with inferior survival, but this is not the case if chemotherapy is given at relapse. More... »

PAGES

578-583

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1989.117

DOI

http://dx.doi.org/10.1038/bjc.1989.117

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1028460723

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2540788


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Small Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etoposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Random Allocation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spiro", 
        "givenName": "S. G.", 
        "id": "sg:person.0744711470.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744711470.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Souhami", 
        "givenName": "R. L.", 
        "id": "sg:person.0736072270.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736072270.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Geddes", 
        "givenName": "D. M.", 
        "id": "sg:person.01304023347.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304023347.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ash", 
        "givenName": "C. M.", 
        "id": "sg:person.01033063717.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033063717.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "H.", 
        "id": "sg:person.01351163513.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351163513.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harper", 
        "givenName": "P. G.", 
        "id": "sg:person.01025232030.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025232030.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tobias", 
        "givenName": "J. S.", 
        "id": "sg:person.01102214516.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102214516.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Partridge", 
        "givenName": "M.", 
        "id": "sg:person.0601000026.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601000026.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brompton Hospital, London, U.K.", 
          "id": "http://www.grid.ac/institutes/grid.439338.6", 
          "name": [
            "Brompton Hospital, London, U.K."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eraut", 
        "givenName": "D.", 
        "id": "sg:person.01010121213.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010121213.29"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00306746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005871877", 
          "https://doi.org/10.1007/bf00306746"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-04", 
    "datePublishedReg": "1989-04-01", 
    "description": "A total of 610 patients with small cell lung cancer were entered into a randomised trial designed to assess the effect of duration of initial chemotherapy on survival. Patients were randomised to receive either four or eight courses of cytotoxic chemotherapy with cyclophosphamide, vincristine and etoposide and also randomised to receive, on disease progression, either second line chemotherapy (methotrexate and doxorubicin) or symptomatic treatment only. In the whole study 196 (32.1%) had limited disease and 414 (67.9%) extensive disease. During initial chemotherapy the response rate (complete and partial responses) after four courses of treatment was 61% with no significant increase in patients receiving eight courses (63%). In those randomised to receive relapse chemotherapy the response rate was improved slightly for those who had originally received four courses of chemotherapy (25.6%) over those receiving eight (18.7%). The overall results show that of the four possible treatment randomizations, four courses of chemotherapy alone is inferior in terms of overall survival (30 weeks median survival) to the other three treatment options (39 weeks median survival, P less than 0.01). In patients responding to initial chemotherapy the disadvantage of four courses of chemotherapy alone was apparent (median survival of 40 weeks versus 49 weeks, P = 0.003) but not if drug treatment was given on relapse. The study shows that limiting treatment to four courses of chemotherapy alone is associated with inferior survival, but this is not the case if chemotherapy is given at relapse.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1989.117", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "59"
      }
    ], 
    "keywords": [
      "courses of chemotherapy", 
      "small cell lung cancer", 
      "cell lung cancer", 
      "initial chemotherapy", 
      "lung cancer", 
      "response rate", 
      "Cancer Research Campaign trial", 
      "second-line chemotherapy", 
      "duration of chemotherapy", 
      "course of treatment", 
      "relapse chemotherapy", 
      "line chemotherapy", 
      "extensive disease", 
      "cytotoxic chemotherapy", 
      "overall survival", 
      "inferior survival", 
      "symptomatic treatment", 
      "treatment options", 
      "disease progression", 
      "drug treatment", 
      "effect of duration", 
      "chemotherapy", 
      "treatment randomization", 
      "patients", 
      "relapse", 
      "significant increase", 
      "treatment", 
      "survival", 
      "cancer", 
      "disease", 
      "trials", 
      "duration", 
      "course", 
      "cyclophosphamide", 
      "vincristine", 
      "progression", 
      "total", 
      "randomization", 
      "overall results", 
      "rate", 
      "options", 
      "study", 
      "cases", 
      "increase", 
      "effect", 
      "results", 
      "disadvantages", 
      "terms", 
      "whole study 196", 
      "study 196", 
      "possible treatment randomizations", 
      "Research Campaign trial", 
      "Campaign trial"
    ], 
    "name": "Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.", 
    "pagination": "578-583", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1028460723"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1989.117"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2540788"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1989.117", 
      "https://app.dimensions.ai/details/publication/pub.1028460723"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_203.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1989.117"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1989.117'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1989.117'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1989.117'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1989.117'


 

This table displays all metadata directly associated to this object as RDF triples.

247 TRIPLES      22 PREDICATES      99 URIs      90 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1989.117 schema:about N0ebb19d5d73f4e12b5433f022944d03b
2 N0ff875f43a6c47dd9e96f072c5a8deab
3 N11668d6599bb4b6c8da54e0ae7fa80c3
4 N2506876166a54d519aa44ab39fbc0703
5 N2d4a643bb1e241c6bd466390e3c026d2
6 N35ff750fda534d0584235b0b5fae006f
7 N3876c28ddc9247958ff4808c4996bf41
8 N568446794bcc4cf38ce991efaba510ff
9 N82e64269f012428f94e6b31f4fdad8aa
10 N88f4e838be914fa8916e12331c8f99db
11 N8dcdcf7e044b482b965f73214820c482
12 N8e89e2fd032f45b4b59ad846d8eb6de6
13 Na468d8ae87d240bba17be62e705da1ff
14 Na5f4745e353c4c7aa0a25677f5d71ccc
15 Nb022b29149374df58be0bca7de009fb1
16 Nb61f255af01842ea99d45062ed3382c9
17 Nde9ffb59bb174e8697f2f3e8585ffd03
18 Ne444bb0e4b8340a998abfc139f24f7db
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N571184815eee40b8bf002c40e51eb424
22 schema:citation sg:pub.10.1007/bf00306746
23 schema:datePublished 1989-04
24 schema:datePublishedReg 1989-04-01
25 schema:description A total of 610 patients with small cell lung cancer were entered into a randomised trial designed to assess the effect of duration of initial chemotherapy on survival. Patients were randomised to receive either four or eight courses of cytotoxic chemotherapy with cyclophosphamide, vincristine and etoposide and also randomised to receive, on disease progression, either second line chemotherapy (methotrexate and doxorubicin) or symptomatic treatment only. In the whole study 196 (32.1%) had limited disease and 414 (67.9%) extensive disease. During initial chemotherapy the response rate (complete and partial responses) after four courses of treatment was 61% with no significant increase in patients receiving eight courses (63%). In those randomised to receive relapse chemotherapy the response rate was improved slightly for those who had originally received four courses of chemotherapy (25.6%) over those receiving eight (18.7%). The overall results show that of the four possible treatment randomizations, four courses of chemotherapy alone is inferior in terms of overall survival (30 weeks median survival) to the other three treatment options (39 weeks median survival, P less than 0.01). In patients responding to initial chemotherapy the disadvantage of four courses of chemotherapy alone was apparent (median survival of 40 weeks versus 49 weeks, P = 0.003) but not if drug treatment was given on relapse. The study shows that limiting treatment to four courses of chemotherapy alone is associated with inferior survival, but this is not the case if chemotherapy is given at relapse.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf Na6116b2633f6438b98347703e7ed67aa
30 Ne57aba68e3ae4dcaac73bc20b85386d6
31 sg:journal.1017082
32 schema:keywords Campaign trial
33 Cancer Research Campaign trial
34 Research Campaign trial
35 cancer
36 cases
37 cell lung cancer
38 chemotherapy
39 course
40 course of treatment
41 courses of chemotherapy
42 cyclophosphamide
43 cytotoxic chemotherapy
44 disadvantages
45 disease
46 disease progression
47 drug treatment
48 duration
49 duration of chemotherapy
50 effect
51 effect of duration
52 extensive disease
53 increase
54 inferior survival
55 initial chemotherapy
56 line chemotherapy
57 lung cancer
58 options
59 overall results
60 overall survival
61 patients
62 possible treatment randomizations
63 progression
64 randomization
65 rate
66 relapse
67 relapse chemotherapy
68 response rate
69 results
70 second-line chemotherapy
71 significant increase
72 small cell lung cancer
73 study
74 study 196
75 survival
76 symptomatic treatment
77 terms
78 total
79 treatment
80 treatment options
81 treatment randomization
82 trials
83 vincristine
84 whole study 196
85 schema:name Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
86 schema:pagination 578-583
87 schema:productId N333eb2dc172e4c3f95e0aaa3873684ab
88 N462dc9256a2b4744b02577a0b3212996
89 N589e5a1b4afd49d795b62564e4de9f57
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028460723
91 https://doi.org/10.1038/bjc.1989.117
92 schema:sdDatePublished 2022-01-01T18:04
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher Nf9dd127d26ac44ffa724dae24f1c1319
95 schema:url https://doi.org/10.1038/bjc.1989.117
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N088714b0807947ac9bcc6c63f44c5044 rdf:first sg:person.0601000026.74
100 rdf:rest N0dead0e6c6824a1a9169f4c9cb6d4bef
101 N0dead0e6c6824a1a9169f4c9cb6d4bef rdf:first sg:person.01010121213.29
102 rdf:rest rdf:nil
103 N0ebb19d5d73f4e12b5433f022944d03b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Antineoplastic Combined Chemotherapy Protocols
105 rdf:type schema:DefinedTerm
106 N0ff875f43a6c47dd9e96f072c5a8deab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Vincristine
108 rdf:type schema:DefinedTerm
109 N11668d6599bb4b6c8da54e0ae7fa80c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Carcinoma, Small Cell
111 rdf:type schema:DefinedTerm
112 N2506876166a54d519aa44ab39fbc0703 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Doxorubicin
114 rdf:type schema:DefinedTerm
115 N2d4a643bb1e241c6bd466390e3c026d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Middle Aged
117 rdf:type schema:DefinedTerm
118 N333eb2dc172e4c3f95e0aaa3873684ab schema:name pubmed_id
119 schema:value 2540788
120 rdf:type schema:PropertyValue
121 N35ff750fda534d0584235b0b5fae006f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Aged
123 rdf:type schema:DefinedTerm
124 N3876c28ddc9247958ff4808c4996bf41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Lung Neoplasms
126 rdf:type schema:DefinedTerm
127 N462dc9256a2b4744b02577a0b3212996 schema:name doi
128 schema:value 10.1038/bjc.1989.117
129 rdf:type schema:PropertyValue
130 N46a9f85b9d1d4d0d8e3f1ae993dc5c62 rdf:first sg:person.0736072270.46
131 rdf:rest Nd7ccb66d4b0a48a1a0c194a8c6209924
132 N46f6197db4fd455c9f0ba78372c62717 rdf:first sg:person.01033063717.01
133 rdf:rest Nd32232ce2dc642729f3dc6703236e1d3
134 N568446794bcc4cf38ce991efaba510ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Adult
136 rdf:type schema:DefinedTerm
137 N571184815eee40b8bf002c40e51eb424 rdf:first sg:person.0744711470.31
138 rdf:rest N46a9f85b9d1d4d0d8e3f1ae993dc5c62
139 N589e5a1b4afd49d795b62564e4de9f57 schema:name dimensions_id
140 schema:value pub.1028460723
141 rdf:type schema:PropertyValue
142 N82e64269f012428f94e6b31f4fdad8aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Humans
144 rdf:type schema:DefinedTerm
145 N88f4e838be914fa8916e12331c8f99db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Methotrexate
147 rdf:type schema:DefinedTerm
148 N8dcdcf7e044b482b965f73214820c482 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Etoposide
150 rdf:type schema:DefinedTerm
151 N8e89e2fd032f45b4b59ad846d8eb6de6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Multicenter Studies as Topic
153 rdf:type schema:DefinedTerm
154 Na468d8ae87d240bba17be62e705da1ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Clinical Trials as Topic
156 rdf:type schema:DefinedTerm
157 Na5f4745e353c4c7aa0a25677f5d71ccc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Cyclophosphamide
159 rdf:type schema:DefinedTerm
160 Na6116b2633f6438b98347703e7ed67aa schema:volumeNumber 59
161 rdf:type schema:PublicationVolume
162 Nb022b29149374df58be0bca7de009fb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Female
164 rdf:type schema:DefinedTerm
165 Nb61f255af01842ea99d45062ed3382c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Drug Administration Schedule
167 rdf:type schema:DefinedTerm
168 Nd32232ce2dc642729f3dc6703236e1d3 rdf:first sg:person.01351163513.41
169 rdf:rest Nfc8be0727f0543e68d3c7a7a2e8041cc
170 Nd7ccb66d4b0a48a1a0c194a8c6209924 rdf:first sg:person.01304023347.52
171 rdf:rest N46f6197db4fd455c9f0ba78372c62717
172 Nde9ffb59bb174e8697f2f3e8585ffd03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Random Allocation
174 rdf:type schema:DefinedTerm
175 Ne444bb0e4b8340a998abfc139f24f7db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Male
177 rdf:type schema:DefinedTerm
178 Ne57aba68e3ae4dcaac73bc20b85386d6 schema:issueNumber 4
179 rdf:type schema:PublicationIssue
180 Ne872e75384f74fe691f7ee440fd9a5c6 rdf:first sg:person.01102214516.82
181 rdf:rest N088714b0807947ac9bcc6c63f44c5044
182 Nf9dd127d26ac44ffa724dae24f1c1319 schema:name Springer Nature - SN SciGraph project
183 rdf:type schema:Organization
184 Nfc8be0727f0543e68d3c7a7a2e8041cc rdf:first sg:person.01025232030.85
185 rdf:rest Ne872e75384f74fe691f7ee440fd9a5c6
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
190 schema:name Oncology and Carcinogenesis
191 rdf:type schema:DefinedTerm
192 sg:journal.1017082 schema:issn 0007-0920
193 1532-1827
194 schema:name British Journal of Cancer
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01010121213.29 schema:affiliation grid-institutes:grid.439338.6
198 schema:familyName Eraut
199 schema:givenName D.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010121213.29
201 rdf:type schema:Person
202 sg:person.01025232030.85 schema:affiliation grid-institutes:grid.439338.6
203 schema:familyName Harper
204 schema:givenName P. G.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025232030.85
206 rdf:type schema:Person
207 sg:person.01033063717.01 schema:affiliation grid-institutes:grid.439338.6
208 schema:familyName Ash
209 schema:givenName C. M.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033063717.01
211 rdf:type schema:Person
212 sg:person.01102214516.82 schema:affiliation grid-institutes:grid.439338.6
213 schema:familyName Tobias
214 schema:givenName J. S.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102214516.82
216 rdf:type schema:Person
217 sg:person.01304023347.52 schema:affiliation grid-institutes:grid.439338.6
218 schema:familyName Geddes
219 schema:givenName D. M.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304023347.52
221 rdf:type schema:Person
222 sg:person.01351163513.41 schema:affiliation grid-institutes:grid.439338.6
223 schema:familyName Quinn
224 schema:givenName H.
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351163513.41
226 rdf:type schema:Person
227 sg:person.0601000026.74 schema:affiliation grid-institutes:grid.439338.6
228 schema:familyName Partridge
229 schema:givenName M.
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601000026.74
231 rdf:type schema:Person
232 sg:person.0736072270.46 schema:affiliation grid-institutes:grid.439338.6
233 schema:familyName Souhami
234 schema:givenName R. L.
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736072270.46
236 rdf:type schema:Person
237 sg:person.0744711470.31 schema:affiliation grid-institutes:grid.439338.6
238 schema:familyName Spiro
239 schema:givenName S. G.
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744711470.31
241 rdf:type schema:Person
242 sg:pub.10.1007/bf00306746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005871877
243 https://doi.org/10.1007/bf00306746
244 rdf:type schema:CreativeWork
245 grid-institutes:grid.439338.6 schema:alternateName Brompton Hospital, London, U.K.
246 schema:name Brompton Hospital, London, U.K.
247 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...